clinically significant anti-Le antibodies in blood donor and patient and importance of their characterization to ensure safe blood transfusion. [1, 2] 
mAteRIAls And methods
The present prospective study from April 2013 to January 2018 comprises three blood donors and four patients who were detected with anti-Le antibody. Donor-clotted samples were initially subjected to mandatory antibody screening and subsequent antibody identification. Antibody screening in patients was performed as a part of mandatory pretransfusion
Original Article
IntRoductIon L ewis (Le) antigens are poorly developed at birth. They are produced by tissue cells and secreted into body fluids including plasma. They are then absorbed onto red cell membrane from plasma. There are three main Le phenotypes, namely Le (a+b−), Le (a−b+), and Le (a−b−). Le antibodies (anti-Le a and anti-Le b ) are usually naturally occurring, predominantly of immunoglobulin (Ig) M (IgM) class and are generally produced by Le (a−b−) individuals. Anti-Le a is more commonly encountered than anti-Le b and may rarely be partially or entirely of IgG class following transfusions of Le antigen positive blood. These anti-Le a IgG antibodies often react at 37°C and Coombs phase and may cause hemolytic transfusion reactions. Here, we share our experience of encountering naturally occurring testing. [3] For all samples under the study, antibody screening and identifications were performed using column agglutination technique (CAT) and dedicated cell panels (Ortho-clinical diagnostics, Inc., Raritan, USA). Enhanced reactivity of antibody was studied using papain-treated panel cells (Ortho-Clinical Diagnostics, Inc., Raritan, USA). On confirmation of antibody, the following investigations were performed for detailed characterization: A. Le antigen typing of donors and patients using special antisera (BioRad/DiaMed, Cressier s/Morat, Switzerland) [4] B. Direct antiglobulin test (DAT) using CAT [4] C. Determination of thermal amplitude and titer of antibody using "pooled O red cells" carrying the corresponding antigen Le (a+b−) [2, 4] D. Determination of IgG class of Le antibody using dithiothreitol-treated serum [2, 4] E. Saliva test to study secretor status. [5] Donor details were obtained from donor card and donor recalling for repeat sampling and confirmation. Patient details were obtained from patient file and personal communication.
Results
Of the 42067 donors and 27287 patients subjected to antibody screening, anti-Le antibody was detected in 3 (0.007%) donors and 4 (0.015%) patients with all expressing Le (a−b−) phenotypes. Tables 1 and 2 dIscussIon Anti-Le a was detected during the routine mandatory antibody screen in the donors. These donors were healthy, young with no history of blood transfusions, or pregnancy. Naturally occurring low-titer anti-Le a of IgG type was detected in two of the three donors who revealed the antibody even after 6-month followup. A 37-year-old male donor had low-titer anti-Le a of IgM type optimally reactive at 4°C and 22°C. Plasma products prepared from these donations were discarded as per the departmental protocol. In an Indian blood donor study, Kahar et al. observed that Le (a−b+) was the most common phenotype with 65.22% frequency, and this finding was comparable to other previous studies.
[ [6] [7] [8] With no Le (a+b+) phenotype observed in the study, interestingly Le (a−b−) was found in 18.26%, which was higher than that reported for Whites (6%). [6] [7] [8] Lack of inheritance of Le gene (lele) leads to expression of the Le (a−b−) phenotype and is much more common in blacks (22%). [1] In the current study, out of the 42067 donors screened for antibody, anti-Le a was detected in three donors and this may be attributed to the high frequency of Le (a−b−) phenotype in Indian blood donor population. This observation reveals the importance of Le antibodies are usually naturally occurring; however, those reacting at 37°C and Coombs phase should not be ignored because they may cause significant posttransfusion in vivo hemolysis. Primarily being IgM type, these hemolysins may activate complement and cause in vivo or in vitro hemolysis. [2] This may explain the anemia with reticulocytosis, elevated lactate dehydrogenase, and positive DAT (C3d) in a 33-year-old unmarried female patient. Quite frequently, Le antibodies are found in the sera of pregnant women; however, none of the female cases under the study were pregnant. A 29-year-old female with chronic iron deficiency anemia had a history (>1 year) of several episodes of the whole blood transfusions elsewhere. This might have triggered the formation of high-titer IgG anti-Le a in a case of preexisting naturally occurring IgM or low-titer IgG anti-Le a . Clinical insignificance of Le antibodies has been observed by previous workers because of their neutralization by Le substances present in the plasma of Le (a−b+) and Le (a+b−) individuals. In addition, other factors such as loss of red cell Le antigens into the plasma, lack of reactivity at 37°C and Coombs phase, IgM nature of antibody and incapability of crossing placenta, and poor antigen development at birth contribute to the clinical insignificance of Le antibody. [1, 2] However, both anti-Le a and anti-Le b have been implicated in cases of mild hemolytic disease of newborn. [9, 10] Like Le, there are other cold-reacting antibodies that at times react at 37°C and cause serological difficulties and at times untoward adverse events. Where the present study detected 7 (0.01%) Le antibodies in 69354-screened individuals with 57% of them clinically significant, Makroo et al. found 4 (0.008%) individuals with antibodies directed against Le system, of which 50% were clinically significant IgG antibodies.
[11] Mladenovic, on the other hand, reported a high prevalence of clinically significant Le antibodies, where 71 of 76 detected anti-Le a and 7of 25 anti-Le b were of IgG type. [12] Likewise, other authors have reported varying prevalence of Le antibodies in their studies. [13] [14] [15] Saliva test could be performed in all individuals, where none revealed Le a or Le b substances, but all were found to be ABH secretors. These findings were in accordance with observation mentioned in the literature. [1, 2] In all individuals, the reactivity of anti-Le a was found to be enhanced by papain-treated panel cells. Anti-Le . [11] For both the patients carrying IgG anti-Le a , incompatible crossmatches were observed. Where the former patient with cholelithiasis showed an incompatible reactivity of 1+ to 2+, high incompatible reactivity (4+) was observed in the patient suffering from iron deficiency anemia. This might be attributed to the high-titer IgG anti-Le a in the later patient. Patients with clinically significant anti-Le a antibody were transfused Le a antigen-negative compatible red cell units without any adverse events. Where the surgical patient with cholelithiasis did not require blood transfusion, the one suffering from iron deficiency anemia received 2 units of compatible red cells with posttransfusion hemoglobin (Hb) value of 8.7 g/dL. Another female patient who received blood transfusion was diagnosed as "anemia under evaluation." Since she carried anti-Le a antibody of IgM type optimally reacting at lower temperature (4°C-22°C), no incompatibility was noticed during crossmatching. She received 2 units of red cell, which were not screened for Le a antigen, and achieved a posttransfusion Hb of 8 g/dL.
conclusIons
We conclude that identification and characterization of any antibody in donor or recipient sample is very crucial to blood safety. Naturally occurring Le antibodies may be clinically significant and at times cause hemolytic transfusion reaction, so their detailed characterization with regard to thermal amplitude and titer is important. All patients with clinically significant Le antibodies should receive compatible Le antigen-negative red cell units to optimize the therapeutic transfusion benefit. However, for patients having only IgM type, low-thermal amplitude Le antibody, with no incompatibility at Coombs phase, antigen typing of donor red cell units may be omitted. This will further help in inventory and cost management of the transfusion services.
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